MedTrace Logo

A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma

NCT01898598 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-05-08

Study results available
· View outcomes & findings →

Summary

This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.

Conditions

Interventions

DRUG

Placebo

Participants will receive matching placebo to vismodegib for 12 weeks.

DRUG

Vismodegib

Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-23
Primary Completion
2016-01-26
Completion
2016-01-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01898598 on ClinicalTrials.gov